These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36513818)

  • 1. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
    Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1406-1413. PubMed ID: 36513818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
    Winkelmann M; Blumenberg V; Rejeski K; Quell C; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    Cytotherapy; 2023 Sep; 25(9):986-992. PubMed ID: 37055322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
    Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
    Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
    Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
    Garcia-Recio M; Wudhikarn K; Pennisi M; Alonso-Trillo R; Flynn J; Shouval R; Afuye AO; Silverberg ML; Batlevi CW; Dahi P; Devlin S; Giralt SA; Halton E; Ruiz J; Maloy M; Mead E; Palomba ML; Santomasso B; Sauter CS; Scordo M; Shah GL; Perales MA
    Transplant Cell Ther; 2021 Mar; 27(3):233-240. PubMed ID: 33781518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
    Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
    Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
    Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
    Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
    Alderuccio JP; Reis IM; Hamadani M; Nachiappan M; Leslom S; Kahl BS; Ai WZ; Radford J; Solh M; Ardeshna KM; Hess BT; Lunning MA; Zinzani PL; Stathis A; Carlo-Stella C; Lossos IS; Caimi PF; Han S; Yang F; Kuker RA; Moskowitz CH
    Clin Cancer Res; 2024 Jan; 30(1):139-149. PubMed ID: 37855688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
    Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
    Mikhaeel NG; Heymans MW; Eertink JJ; de Vet HCW; Boellaard R; Dührsen U; Ceriani L; Schmitz C; Wiegers SE; Hüttmann A; Lugtenburg PJ; Zucca E; Zwezerijnen GJC; Hoekstra OS; Zijlstra JM; Barrington SF
    J Clin Oncol; 2022 Jul; 40(21):2352-2360. PubMed ID: 35357901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
    Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
    Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.